These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2256443)

  • 1. Pharmacokinetic comparison of two carbamazepine slow-release formulations.
    Jensen PK; Møller A; Gram L; Jensen NO; Dam M
    Acta Neurol Scand; 1990 Aug; 82(2):135-7. PubMed ID: 2256443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bioavailability of carbamazepine from two slow-release preparations.
    Reunanen M; Heinonen EH; Nyman L; Anttila M
    Epilepsy Res; 1992 Mar; 11(1):61-6. PubMed ID: 1563339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR).
    Stevens RE; Limsakun T; Evans G; Mason DH
    J Pharm Sci; 1998 Dec; 87(12):1531-4. PubMed ID: 10189261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects.
    Larkin JG; McLellan A; Munday A; Sutherland M; Butler E; Brodie MJ
    Br J Clin Pharmacol; 1989 Mar; 27(3):313-22. PubMed ID: 2655682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients.
    McKee PJ; Blacklaw J; Carswell A; Gillham RA; Brodie MJ
    Br J Clin Pharmacol; 1993 Sep; 36(3):257-61. PubMed ID: 9114913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of dosing frequency of carbamazepine with a slow-release preparation.
    Sivenius J; Heinonen E; Lehto H; Järvensivu P; Anttila M; Ylinen A; Riekkinen P
    Epilepsy Res; 1988; 2(1):32-6. PubMed ID: 3197677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences.
    Hoffmann C; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Möritz KU; Siegmund W
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):496-503. PubMed ID: 9401830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients.
    McKee PJ; Blacklaw J; Butler E; Gillham RA; Brodie MJ
    Br J Clin Pharmacol; 1991 Jul; 32(1):99-104. PubMed ID: 1888646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients.
    Thakker KM; Mangat S; Garnett WR; Levy RH; Kochak GM
    Biopharm Drug Dispos; 1992 Nov; 13(8):559-69. PubMed ID: 1421050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product.
    Mahmood I; Chamberlin N
    Br J Clin Pharmacol; 1998 Mar; 45(3):241-6. PubMed ID: 9517367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation.
    Reunanen M; Heinonen E; Anttila M; Järvensivu P; Lehto H; Hokkanen E
    Epilepsy Res; 1990 Jul; 6(2):126-33. PubMed ID: 2387286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation, release characteristics and bioavailability study of oral monolithic matrix tablets containing carbamazepine.
    Barakat NS; Elbagory IM; Almurshedi AS
    AAPS PharmSciTech; 2008; 9(3):931-8. PubMed ID: 18686038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects.
    Bareggi SR; Tata MR; Guizzaro A; Pirola R; Parisi A; Monza CG
    Int Clin Psychopharmacol; 1994; 9(1):9-16. PubMed ID: 8195585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates.
    Aldenkamp AP; Rentmeester T; Hulsman J; Majoie M; Doelman J; Diepman L; Schellekens A; Franken M; Olling M
    Eur J Clin Pharmacol; 1998 Apr; 54(2):185-92. PubMed ID: 9626926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.
    Patsalos PN
    Br J Clin Pharmacol; 1990 May; 29(5):574-7. PubMed ID: 2350535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy.
    Garnett WR; Levy B; McLean AM; Zhang Y; Couch RA; Rudnic EM; Pellock JM; Belendiuk GW
    Epilepsia; 1998 Mar; 39(3):274-9. PubMed ID: 9578044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine.
    Bialer M; Arcavi L; Sussan S; Volosov A; Yacobi A; Moros D; Levitt B; Laor A
    Epilepsy Res; 1998 Nov; 32(3):371-8. PubMed ID: 9839777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine.
    Bialer M; Yacobi A; Moros D; Levitt B; Houle JM; Munsaka MS
    Epilepsia; 1998 May; 39(5):513-9. PubMed ID: 9596204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of epilepsy in mentally retarded patients with a slow-release carbamazepine preparation.
    Kaski M; Heinonen E; Sivenius J; Tuominen J; Anttila M
    J Ment Defic Res; 1991 Jun; 35 ( Pt 3)():231-9. PubMed ID: 1920391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.